Skip to main content

Man in custody after hours-long RV standoff outside Walmart

NJ: FL MAN IN CUSTODY AFTER HOURS-LONG RV STANDOFF

Click here for updates on this story

    LUMBERTON, New Jersey (WPVI) — A Florida man was taken into custody Tuesday after a 16-hour standoff in an RV parked at a Walmart on Route 38 in Lumberton, according to police.

Authorities identified the suspect as Blake Reed, 38, of Florida. He is charged with robbery and weapons offenses. Police said they received information that Reed might have had a flamethrower inside the RV.

The incident began around 11 p.m. Monday following a dispute in the Walmart parking lot, police said.

After attempting for about 16 hours to get Reed to surrender, officers entered the RV with pepper spray at approximately 3:15 p.m. and removed him from the camper. Reed was placed in an ambulance and taken to a hospital.

During the standoff, law enforcement used drones, K-9 units, robots and a battering ram in efforts to persuade Reed to leave the vehicle. By mid-afternoon, authorities began dismantling the RV with an armored vehicle.

Police diverted customers away from the area of the parking lot where the operation was underway.

Loved ones who remained at the scene throughout the day said Reed had been experiencing what they described as a mental health crisis. They said he lived in the RV and traveled around the country performing at state and community fairs.

“He’s a wonderful guy; he just had a break. And he’s going to be fine. And I’m so happy that we happened to be here,” family friend Kay said.

Kay also said, “I heard he hit his head really bad yesterday and it could’ve caused a concussion. We don’t know.”

Later, she added, “So grateful. So grateful to God that he’s okay.”

According to police, Reed suffered minor injuries during the incident. No officers were injured.

The investigation remains ongoing, and Walmart had not reopened.

Please note: This story was provided to CNN Wire by an affiliate and does not contain original CNN reporting. This content carries a strict local market embargo. If you share the same market as the contributor of this article, you may not use it on any platform.

Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial

Stock photo of a doctor examining a patient's skin. (Lordhenrivoton/STOCK PHOTO/Getty Images)(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients whose high-risk melanoma had been surgically removed.The combination treatment regimen pairs the personalized vaccine with Merck's Keytruda, which had previously been used to treat the cancer alone.The treatment showed a 49% reduction of melanoma return after patients underwent surgery and a 59% reduction of metastasization of the cancer to distant organs.Key questions surrounding regulatory review of the vaccine remain.The Food and Drug Administration has not yet approved the vaccine. The agency will review the full data once it has been collected and submitted.While the FDA has already approved other cancer vaccines, this new treatment represents a step forward in the field as it uses mRNA technology and personalized treatment for each patient.Merck and Moderna plan to present data at an upcoming international medical meeting where they hope to engage regulators on filing submissions for approval of the regimen, the companies said in a joint press release.Dr. Ahmad Tarhini, an oncologist at the H. Lee Moffitt Cancer Center & Research Institute, told ABC News that he expects the treatment to be approved based on very positive trial results and made available to patients likely by early 2027.The vaccine uses genetic information from patients' individual tumors to identify and attack the cancer."It's what we call individualized neoantigen therapy, where we take the cancer itself, we do genetic sequencing and try to define a unique mutational fingerprint of the cancer itself," Tarhini said.Melanoma is the deadliest form of skin cancer, with about 112,000 new cases expected in 2026, according to the American Cancer Society.The treatment is considered relatively safe, according to the companies. The most common side effects include fatigue, sore arm and chills.Treatments utilizing mRNA technologies are being used in trials for other forms of cancer, including that of the bladder, kidney, lungs, stomach and pancreas, according to Tarhini."I think it will certainly improve the outcome of our patients," Tarhini said. "We are, you know, excited about this development. My expectation is this will eventually change the standard care of our patients."Copyright © 2026, ABC Audio. All rights reserved.
Read Next Story